Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Samsung’s Humira Biosimilar Set For Filings As It Completes Phase III

This article was originally published in PharmAsia News

Executive Summary

The Samsung Group's biopharmaceutical affiliate Samsung Bioepis has successfully completed Phase III global clinical trials for its biosimilar version of Humira, taking another step forward in its ambitions to become a global leader in the development of biosimilars.

You may also be interested in...



Biosimilar Pathway Quickly Becoming Crowded In U.S.

Interactive chart of growing 351(k) pipeline shows that while Phase III is dominated by big players, pure-play biosimilar companies are beginning to emerge.

Should Global Pharmas Focus More On Korean Partners?

PharmaVentures’ Adrian Dawkes talks about how COVID-19 will impact pharma deals going forward and how Korean firms in particular may be able to grab opportunities in the global arena. 

Bio Korea: R&D Strategies To Tackle Global COVID-19 Market

The Bio Korea meeting included a discussion around the challenges faced by Korean developers of COVID-19 therapies and vaccines and how they should approach the global market. Cooperation and production technology will be key.

Topics

Related Companies

UsernamePublicRestriction

Register

SC089073

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel